An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Phase 1 Terminated
69 enrolled 47 charts
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Phase 1 Terminated
84 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
T-allo10
Phase 1 Terminated
5 enrolled 18 charts
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Phase 1 Terminated
11 enrolled
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
Phase 1 Terminated
13 enrolled
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Phase 1 Terminated
1 enrolled
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
16 enrolled 10 charts
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
RID
Phase 1 Terminated
12 enrolled
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Phase 1 Terminated
2 enrolled
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
Phase 1 Terminated
4 enrolled
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1 Terminated
10 enrolled
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Phase 1 Terminated
1 enrolled
RLI
Phase 1 Terminated
7 enrolled
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Phase 1 Terminated
5 enrolled
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
Phase 1 Terminated
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Phase 1 Terminated
8 enrolled
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Phase 1 Terminated
20 enrolled
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Phase 1 Terminated
6 enrolled
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Phase 1 Terminated
10 enrolled
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Phase 1 Terminated
2 enrolled
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Phase 1 Terminated
11 enrolled
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Phase 1 Terminated
44 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Phase 1 Terminated
4 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
Phase 1 Terminated
31 enrolled
ANGELA
Phase 1 Terminated
5 enrolled
ALDI
Phase 1 Terminated
6 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
30 enrolled
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Phase 1 Terminated